BIOCOMPATIBLE METHOD OF FUNCTIONALISING SUBSTRATES WITH INERT SURFACES
20170219467 · 2017-08-03
Inventors
Cpc classification
G01N33/54393
PHYSICS
C12Q1/24
CHEMISTRY; METALLURGY
G01N1/4077
PHYSICS
G01N33/54353
PHYSICS
International classification
B01D65/08
PERFORMING OPERATIONS; TRANSPORTING
C12Q1/24
CHEMISTRY; METALLURGY
Abstract
Biocompatible methods of functionalising inert surfaces for use in biological applications are described. The methods employ the use of synthetic constructs of the generic structure F-S-L (where F is a functional moiety, S is a spacer selected to provide a construct that is dispersible in water, and L is a diacyl- or dialkyl-glycerophospholipid). An object of the invention is to localise or immobilise functional moieties to the inert surface of a substrate wherein the surface is comprised of glass, silver, polyamide, polycarbonate, polypropylene, polyethersulfone, polytetrafluoroethylene or polyvinylidene fluoride, and the substrate is comprised of a fibre, membrane, microsphere or nanosphere.
Claims
1) A method of functionalising an inert surface of a substrate comprising the step of contacting the surface of the substrate with an aqueous dispersion of a construct of the structure F-S-L, where F is a functional moiety, S is a spacer selected to provide a construct that is dispersible in water, and L is a diacyl- or dialkyl-glycerophospholipid.
2) The method of claim 1 comprising the steps of: contacting the surface of the substrate with an aqueous dispersion of a construct of the structure F-S-L; and then washing the surface of the substrate with an aqueous vehicle to provide the functionalised surface.
3) The method of claim 1 where the inert surface consists of a substance selected from the group consisting of: glass, silver, polyamide, polycarbonate, polypropylene, polyethersulfone, polytetrafluoroethylene and polyvinylidene fluoride.
4) The method of claim 1 where the substrate is a fibre, membrane, microsphere or nanosphere.
5) The method of claim 4 where the substrate is a membrane comprised of cross-linked, fused or woven fibres.
6) The method of claim 5 where the membrane is a filtration membrane.
7) The method of claim 4 where the substrate is a microsphere.
8) The method of claim 7 where the microsphere is a polycarbonate microsphere.
9) The method of claim 1 where the construct is a water dispersible construct of the structure: ##STR00016## where F is a functional moiety, M is a monovalent cation, R.sup.1 and R.sup.2 are independently a C.sub.14-20 acyl, alkyl or alkenyl group, preferably a C.sub.16-18 acyl, alkyl or alkenyl group, and S is a spacer selected to provide a construct that is dispersible in water.
10) The method of claim 9 where the construct is a water dispersible construct of the structure: ##STR00017## where R.sup.1 and R.sup.2 are independently a C.sub.13-19 alkyl or alkenyl group, preferably a C.sub.15-17 alkyl or alkenyl group.
11) A substrate comprising a construct of the structure F-S-L localised to its surface where the surface is inert, F is a functional moiety, S is a spacer selected to provide a construct that is dispersible in water, and L is a diacyl- or dialkyl-glycerophospholipid.
12) The substrate of claim 11 where the surface is polycarbonate.
13) The substrate of claim 11 where the substrate is fibre.
14) The substrate of claim 11 where the substrate is a membrane.
15) The substrate of claim 11 where the substrate is a microsphere.
16) A substrate having a functionalised surface prepared according to the method of claim 1.
17) A filter assembly comprising a membrane functionalised according to claim 1.
Description
BRIEF DESCRIPTION OF DRAWINGS
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
DETAILED DESCRIPTION
[0050] In the method of the invention a functionalising moiety is localised (as defined) to the surface of a substrate where the surface is inert (as defined). The association between the construct F-S-L comprising the functionalising moiety (F) is sufficiently strong under biocompatible (as defined) conditions to permit use in a variety of biological applications including sample analysis and preparation. These biological applications include blocking and washing steps using aqueous solutions that, save for the strength of the association between the construct and the surface of the substrate, would be expected to remove the functionalising moiety.
[0051] Surprisingly it has been found that the association between the construct and the surface is strong enough to be maintained during repeated washing steps irrespective of the hydrophobicity or hydrophilicity of the surface of the substrate. Without wishing to be bound by theory it is believed the strength of the association between the construct and the surface of the substrate could be attributable to the construct spontaneously forming a layer enveloping the surface of the substrate. It is suggested that such envelopment is favoured by the substrate being in the form of a fibre or thread, but this suggestion does not exclude the possibility that envelopment occurs in discrete areas of the surface of the substrate, e.g. as a lining of the inner walls of the channels present in a porous substrate, such as a filter membrane. Without wishing to be bound by theory it is hypothesised that the formation of mono- or bilayers as illustrated schematically in
[0052] Products supplied under the trade name PHENEX™ (Phenomenex) are examples of polyamide (NYLON™) filter membranes. Products supplied under the trade name GH POLYPRO™ (Gelman) and the trade name METRICEL™ (Pall Corporation) are examples of polypropylene filter membranes. Products supplied under the trade name GELMAN TF™ (Gelman) are examples of filter membranes with a polytetrafluoroethylene (TEFLON™) surface. Despite the surface of these substrates ranging from the hydrophobic to the hydrophilic, all have been shown to be substrates capable of being functionalised according to the method of the invention. Other substrates that may be functionalised according to the method of the invention include the products supplied under the trade name DURAPOR™ (Millipore) which are filter membranes with a polyvinylidene fluoride (KYNAR™, HYLAR™) surface.
[0053] The surface of the substrate constituting a filter membrane employed in the analysis and preparation of biological samples, such as plasma and serum, is purposefully selected to be antifouling. The antifouling properties prevent, or at least substantially mitigate, non-specific binding of components of the biological samples to the membrane. The avoidance of non-specific binding to the filter membrane is desirable to avoid clogging of the membrane and cross-contamination of biological samples with repeated use. The antifouling characteristic of the surface of the substrate constituting a filter membrane necessarily limits the ability to introduce functionalities that promote selective binding of minor components of the biological sample to the membrane and consequential concentration in situ or following elution.
[0054] The method of the invention permits the functionalization of a surface that has purposefully been selected to be antifouling. The functionalization is achieved by the localisation of the functionalising moiety to the surface under conditions that are biocompatible and do not affect the structural integrity of the substrate. Use of the method of the invention enables novel sample analysis and preparation procedures to be employed as illustrated with reference to the Figures of the accompanying drawings and the following examples.
EXAMPLE 1
[0055] Dispersions of the aminopropyl derivative of blood group A trisaccharide (A.sub.tri-S.sub.1) and the construct A.sub.tri-sp-Ad-DOPE (FSL-A) were prepared at a concentration of 0.2 mM in PBS containing 0.01% polyoxyethylene (20) sorbitan monolaureate (TWEEN™ 20) and 1% inkjet ink (magenta).
##STR00011##
[0056] A.sub.tri-S.sub.1 (as described in the specification accompanying international application no. PCT/NZ2005/000052 (publ. no. WO 2005/090368))
##STR00012##
[0057] FSL-A (as described in the specification accompanying international application no. PCT/NZ2005/000052 (publ. no. WO 2005/090368))
[0058] The dispersions were loaded into separate ink cartridges of an EPSON STYLUS™ T21 piezoelectric inkjet printer. The identity of the dispersion and substrate were printed onto samples of the following substrates: glass fibre filter paper GC-50 (Advanetc); glass microfiber filter GF/B (Whatman); nylon membrane filter 0.2 μm (Phenomenex) filter paper 1 (Whatman); polypropylene filter membrane (Gelman Sciences); METRICEL™ filter membrane GA-3 1.2 μm (Gelman Sciences); TEFLON™ filter membrane TF-200 0.2 μm (Gelman Instrument Company); glass fibre filter A/E (Pall Life Sciences), nylon 66 filter membrane 0.45 μm (Schleicher & Schuell) and silk. The printed samples of substrate were then immersed in a solution of 2% (w/v) bovine serum albumin (BSA) in PBS for 1 hour prior to being rinsed and the surface of the substrate being flooded with a 1 in 5 dilution in BSA of anti-A immunoglobulin (EPICLONE™ monoclonal, CSL Limited) and incubated for 30 minutes, or flooded with a 1 in 2 dilution in BSA of O group serum and incubated for 1 hour. The surfaces of the substrates were then washed 6 times with PBS prior to being flooded with a 1:400 dilution of alkaline phosphatase conjugated sheep anti-mouse immunoglobulin (Chemicon) and incubated for 30 minutes. The surfaces of the substrates were then washed 6 times with PBS followed by a washing of substrate buffer (100 mM Tris, 100 mM NaCl, 50 mM MgCl.sub.2, pH 9.5). The substrate buffer washed surfaces of the substrates were then flooded with a 1 in 50 dilution in substrate buffer of the chromogenic substrate (18.75 mg/mL nitro blue tetrazolium chloride and 9.4 mg/mL 5-bromo-4-chloro-3-indolyl phosphate, toluidine salt) (NBTC-BCIP) in 67% DMSO (Roche)) for about 10 minutes. The chromogenic reaction was stopped by rinsing the surface of each substrate with deionised water. The appearance of the surface of each substrate following incubation with the chromogenic substrate is provided in
EXAMPLE 2
[0059] Dispersions of the construct B.sub.tri-sp-Ad-DOPE (FSL-B) and its monoacyl counterpart (monoacyl-B) were prepared at a concentration of 0.4 mM in PBS containing 0.01% polyoxyethylene (20) sorbitan monolaureate (TWEEN™ 20) and 1% inkjet ink (magenta).
##STR00013##
[0060] FSL-B (as described the specification accompanying international application no. PCT/NZ2005/000052 (publ. no. WO 2005/090368))
##STR00014##
[0061] Monoacyl-B (as described in the specification accompanying international application no. PCT/NZ2005/000052 (publ. no. WO 2005/090368))
[0062] The dispersions were loaded into separate ink cartridges of an EPSON STYLUS™ T21 piezoelectric inkjet printer. The identity of the dispersion and substrate were printed onto samples of the following substrates: glass fibre filter paper GC-50 (Advanetc); glass microfiber filter GF/B (Whatman); nylon membrane filter 0.2 μm (Phenomenex); filter paper 1 (Whatman); polypropylene filter membrane (Gelman Sciences); METRICEL™ filter membrane GA-3 1.2 μm (Gelman Sciences); TEFLON filter membrane TF-200 0.2 μm (Gelman Instrument Company); glass fibre filter A/E (Pall Life Sciences), nylon 66 filter membrane 0.45 μm (Schleicher & Schuell) and silk. The printed samples of substrate were then immersed in a solution of 2% (w/v) bovine serum albumin (BSA) in PBS for 1 hour prior to being rinsed and the surface of the substrate being flooded with a 1 in 5 dilution in BSA of anti-B immunoglobulin (EPICLONE™ monoclonal, CSL Limited) and incubated for 30 minutes. The surfaces of the substrates were then washed 6 times with PBS prior to being flooded with a 1:400 dilution of alkaline phosphatase conjugated sheep anti-mouse immunoglobulin (Chemicon) and incubated for 30 minutes. The surfaces of the substrates were then washed 6 times with PBS followed by a washing of substrate buffer (100 mM Tris, 100 mM NaCl, 50 mM MgCl.sub.2, pH 9.5). The substrate buffer washed surfaces of the substrates were then flooded with a 1 in 50 dilution in substrate buffer of the chromogenic substrate (18.75 mg/mL nitro blue tetrazolium chloride and 9.4 mg/mL 5-bromo-4-chloro-3-indolyl phosphate, toluidine salt) (NBTC-BCIP) in 67% DMSO (Roche)) for about 10 minutes. The chromogenic reaction was stopped by rinsing the surface of each substrate with deionised water. The appearance of the surface of each substrate following incubation with the chromogenic substrate is provided in
EXAMPLE 3
[0063] Dispersions of the constructs FSL-A and FSL-Biotin at a concentration of 0.5 mg/ml (circa 6 mM) in PBS were painted onto glass fibre threads using a brush. The painted thread was allowed to dry between applications of subsequent layers.
##STR00015##
[0064] FSL-Biotin (as described in the specification accompanying international application no. PCT/NZ2008/000266 (publ. no. WO 2009/048343))
[0065] A glass fibre thread painted with 1 to 3 layers of the dispersion of FSL-A was immersed in a solution of 2% (w/v) bovine serum albumin (BSA) in PBS for 1 hour prior to being rinsed and immersed in a 1 in 5 dilution in BSA of anti-B immunoglobulin (EPICLONE™ monoclonal, CSL Limited) for 30 minutes. The painted glass fibre thread was then washed 6 times with PBS prior to being immersed in a 1:400 dilution of alkaline phosphatase conjugated sheep anti-mouse immunoglobulin (Chemicon) for 30 minutes. The thread was then washed 6 times with PBS followed by a washing of substrate buffer (100 mM Tris, 100 mM NaCl, 50 mM MgCl.sub.2, pH 9.5). The washed thread was then immersed in a 1 in 50 dilution in substrate buffer of the chromogenic substrate (18.75 mg/mL nitro blue tetrazolium chloride and 9.4 mg/mL 5-bromo-4-chloro-3-indolyl phosphate, toluidine salt) (NBTC-BCIP) in 67% DMSO (Roche)) for about 10 minutes. The chromogenic reaction was stopped by immersing the thread in deionised water. The appearance of threads coated with 1, 2 or 3 layers of FSL-A following incubation with the chromogenic substrate is provided in
[0066] A glass fibre thread painted with 1 to 3 layers of the dispersion of FSL-Biotin was immersed in a solution of 2 μg/mL streptavidin-alkaline phosphatase conjugate in bovine serum albumin (BSA) in PBS for 1 hour prior to being washed 6 times with PBS followed by a washing of substrate buffer (100 mM Tris, 100 mM NaCl, 50 mM MgCl, pH 9.5). The washed thread was then immersed in a 1 in 50 dilution in substrate buffer of the chromogenic substrate (18.75 mg/mL nitro blue tetrazolium chloride and 9.4 mg/mL 5-bromo-4-chloro-3-indolyl phosphate, toluidine salt) (NBTC-BCIP) in 67% DMSO (Roche)) for about 15 minutes. The chromogenic reaction was stopped by immersing the thread in deionised water. The appearance of threads coated with 1, 2 or 3 layers of FSL-Biotin following incubation with the chromogenic substrate is provided in
[0067] The ability to functionalise the otherwise inert surface of a substrate allows a number of novel applications to be developed. For example, immunosorbent assays may be performed with greater facility using laboratory filter assemblies such as those illustrated in cross section in
EXAMPLE 4
[0068] Localising Functional Moieties to the Surface of Monodisperse Polycarbonate Microspheres
[0069] An aliquot (2 to 3 μL) of polycarbonate microspheres (MAKROLON™ 2808, Nanomi B.V.) of uniform diameter (20 μM±3%) (monodisperse) was mixed with a 30 μL volume of a 500 μg/mL dispersion in PBS of the construct designated FSL-Biotin. The mixture was incubated at room temperature (circa 22° C.) for 30 minutes prior to washing of the microspheres by repeated (three times) centrifugation and resuspension in PBS. The functionalised and washed microspheres were finally resuspended in a volume of 200 μL of PBS. An aliquot (2 to 3 μL) of the same polycarbonate microspheres were also suspended in a volume of 200 μL of PBS without prior mixing with a dispersion of construct and used as a control.
[0070] A 50 μL volume of the suspension of functionalised and washed microspheres was mixed with a 50 μL volume of a 100 μg/mL solution in PBS of avidin conjugated AlexaFlour™ 488 (Life Technologies). Similarly, a 50 μL volume of the suspension of untreated (control) polycarbonate microspheres was mixed with a 50 μL volume of a 100 μL/mL solution in PBS of avidin conjugated. AlexaFlour™ 488 (Life Technologies). Both mixtures were incubated at 37° C. for 30 minutes prior to washing of the microspheres by repeated (three times) centrifugation and resuspension in PBS as before. The washed microspheres were resuspended in a volume of PBS sufficient to permit examination by light and fluorescence microscopy. Only the functionalised microspheres were observed to fluoresce (see
EXAMPLE 5
[0071] Localising RBCs to the Surface of Monodisperse Polycarbonate Microspheres Via Avidin-Biotin Conjugation
[0072] Biotin was localised to the surface of O-group RBCs using the construct designated FSL-Biotin. A 50 μL volume of packed RBCs was mixed with a 50 μL volume of a 200 μg/mL dispersion of PBS of the construct. The mixture was incubated at 37° C. for 2 hours prior to washing of the cells by repeated (three times) centrifugation and resuspension in PBS. The washed and modified RBCs (kodecytes) were finally resuspended in a volume of PBS at a density of 20% of the PCV.
[0073] An aliquot (2 to 3 μL) of polycarbonate microspheres (MAKROLON™ 2808, Nanomi B.V.) of uniform diameter (20 μM±3%) (monodisperse) was mixed with a 30 μL volume of a 200 μg/mL dispersion in PBS of the construct designated FSL-Biotin. The mixture was incubated at room temperature (circa 22° C.) for 30 minutes prior to washing of the functionalised microspheres by repeated (three times) centrifugation and resuspension in PBS. The functionalised and washed microspheres were finally resuspended in a volume of 200 μL of PBS.
[0074] A 50 μL volume of the suspension of the functionalised and washed microspheres was mixed with a 50 μL volume of a 200 μg/mL solution in PBS of streptavidin and the mixture incubated at room temperature (circa 22° C.) for 30 minutes. Following incubation the avidinylated functionalised microspheres were washed by repeated (three times) centrifugation and resuspended in PBS.
[0075] A 50 μL volume of the FSL-Biotin kodecytes suspended in PBS at a density of 20% PCV was mixed with a 20 μL volume of the suspension of avidinylated functionalised microspheres. A 20 μL volume of O-group RBCs resuspended in PBS at a density of 20% PCV was mixed with a 20 μL volume of the avidinylated functionalised microspheres as a control. Both mixtures were incubated at 37° C. for 1 hours before dilution with 100 μL PBS to permit viewing by light microscopy. FSL-Biotin kodecytes were observed to be localised to the surface of the avidinylated functionalised microspheres only (see
EXAMPLE 6
[0076] Localising RBCs to the Surface Of Monodisperse Polycarbonate Microspheres Via Antibody-antigen Cross-Reactivity
[0077] Blood group A-antigen (A.sub.tri) was localised to the surface of O-group RBCs using the construct designated FSL-A.sub.tri. A 50 μL volume of the packed RBCs was mixed with a 50 μL volume of a 200 μg/mL dispersion in PBS of the construct. The mixture was incubated at 37° C. for 2 hours prior to washing of the cells by repeated (three times) centrifugation and resuspension in PBS. The washed and modified RBCs (kodecytes) were finally resuspended in a volume of PBS at a density of 20% of the PCV.
[0078] An aliquot (2 to 3 μL) of polycarbonate microspheres (MAKROLON™ 2808, Nanomi R.V.) of uniform diameter (20 μM±3%) (monodisperse) was mixed with a 30 μL volume of a 200 μg/mL dispersion in PBS of the construct designated FSL-A.sub.tri. The mixture was incubated at room temperature (circa 22° C.) for 30 minutes prior to washing of the functionalised microspheres by repeated (three times) centrifugation and resuspension in PBS. The functionalised and washed microspheres were finally resuspended in a volume of 200 μL of PBS.
[0079] A 50 μL volume of the suspension of the functionalised and washed microspheres was mixed with a 50 μL volume of undiluted monoclonal anti-A (Epiclone, CSL Limited) and the mixture incubated at room temperature (circa 22° C.) for 60 minutes. Following incubation the antibody bound functionalised microspheres were washed by repeated (three times) centrifugation and resuspended in PBS.
[0080] A 20 μL volume of the suspension of FSL-A.sub.tri kodecytes resuspended in PBS at a density of 20% PCV was mixed with a 20 μL volume of the antibody bound functionalised microspheres. A 20 μL volume of O-group RBCs resuspended in PBS at a density of 20% PCV was mixed with a 20 μL volume of the suspension of the antibody bound functionalised microspheres as a first control. A 20 μL volume of the suspension of FSL-A.sub.tri kodecytes resuspended in PBS at a density of 20% PCV was mixed with a 20 μL volume of the functionalised microspheres obtained prior to mixing and incubation with the undiluted monoclonal anti-A (Epiclone, CSL Limited) as a second control. All mixtures were incubated at room temperature (circa 22° C.) for 1½ hours before dilution by the addition of a 200 μL volume of PBS to permit viewing by light microscopy.
[0081] RBCs were observed to be localised to the surface of the treated and washed polycarbonate microspheres only where antibody was present (see
EXAMPLE 7
[0082] Localising Bacteria to the Surface of Monodisperse Polycarbonate Microspheres Via Avidin-Biotin Conjugation
[0083] Biotin was localised to the surface of two species of bacterium (Staphylococcus sarophyticus and Micrococcus luteus) using the construct designated FSL-Biotin. A 50 μL volume of a 200 μg/mL dispersion in PBS of the construct was mixed with a colony of each bacterium. Each mixture was incubated at 37° C. for 2 hours prior to washing of the bacterial cells by repeated (three times) centrifugation and resuspension in PBS. The washed and treated bacterial cells were finally resuspended in a 300 μL volume of PBS.
[0084] An aliquot (2 to 3 μL) of polycarbonate microspheres (MAKROLON™ 2808, Nanomi B.V.) of uniform diameter (20 μM±3%) (monodisperse) was mixed with a 30 μL volume of a 200 μg/mL dispersion in PBS of the construct designated FSL-Biotin. The mixture was incubated at room temperature (circa 22° C.) for 30 minutes prior to washing of the functionalised microspheres by repeated (three times) centrifugation and resuspension in PBS. The functionalised microspheres were finally resuspended in a volume of 200 μL of PBS. A 50 μL volume of the functionalised microspheres was mixed with a 50 μL volume of a 2 mg/mL solution in PBS of avidin and the mixture incubated at room temperature (circa 22° C.) for 30 minutes. Following incubation the avidinylated functionalised microspheres were washed by repeated (three times) centrifugation and resuspension in PBS.
[0085] A 50 μL volume of the suspension of FSL-Biotin modified bacterial cells was mixed with a 50 μL volume of the avidinylated functionalised microspheres. The mixture was incubated at room temperature (circa 22° C.) for 30 minutes before examination by light microscopy. Bacterial cells were observed to be localised to the surface of the avidinylated functionalised microspheres (see
[0086] Although the invention has been described with reference to embodiments or examples it should be appreciated that variations and modifications may be made to these embodiments or examples without departing from the scope of the invention. Where known equivalents exist to specific elements, features or integers, such equivalents are incorporated as if specifically referred to in this specification. In particular, variations and modifications to the embodiments or examples that include elements, features or integers disclosed in and selected from the referenced publications are within the scope of the invention unless specifically disclaimed. The advantages provided by the invention and discussed in the description may be provided in the alternative or in combination in these different embodiments of the invention. Although the invention has been described with reference to embodiments or examples it should be appreciated that variations and modifications may be made to these embodiments or examples without departing from the scope of the invention. Where known equivalents exist to specific elements, features or integers, such equivalents are incorporated as if specifically referred to in this specification. In particular, variations and modifications to the embodiments or examples that include elements, features or integers disclosed in and selected from the referenced publications are within the scope of the invention unless specifically disclaimed. The advantages provided by the invention and discussed in the description may be provided in the alternative or in combination in these different embodiments of the invention.